{
  "id": 520,
  "text": "# NCCN宫颈癌指南2024.V1版较2023.V1版更新内容（续） CERV-F 1/3 宫颈癌的全身治疗 鳞状细胞癌、腺癌或腺鳞癌 ![](images/5f3249131da5b7102251609d0c3f7f2fd153a2a89bf8517ac68126c2586aaade.jpg) # NCCN宫颈癌指南2024.V1版较2023.V1版更新内容（续） CERV-F 1/3 宫颈癌的全身治疗——宫颈小细胞神经内分泌癌 # CERV-F 2 of 3 Small Cell NECC ↓ Recurrent or Metastatic Disease Second-line orSubsequent Therapy; OtherRecommended Regimens:lrinotecanchanged fromcategory 2Btocategory A Footnote f added: NCCN Guidelines for the Management of Immunotherapy-Related Toxicities.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: # NCCN宫颈癌指南2024.V1版较2023.V1版更新内容（续） CERV-F 1/3 宫颈癌的全身治疗 鳞状细胞癌、腺癌或腺鳞癌 ![](images/5f3249131da5b7102251609d0c3f7f2fd153a2a89bf8517ac68126c2586aaade.jpg) # NCCN宫颈癌指南2024.V1版较2023.V1版更新内容（续） CERV-F 1/3 宫颈癌的全身治疗——宫颈小细胞神经内分泌癌 # CERV-F 2 of 3 Small Cell NECC ↓ Recurrent or Metastatic Disease Second-line orSubsequent Therapy; OtherRecommended Regimens:lrinotecanchanged fromcategory 2Btocategory A Footnote \n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "在新版的NCCN宫颈癌指南中，针对复发或转移性疾病的治疗方案，伊立替康的应用类别有了显著变化。从之前的2B类提升到A类。这意味着伊立替康作为二线或后续治疗方案中的推荐药物，其临床证据得到了更高程度的认可和支持。这样的变化可能反映了伊立替康在相关治疗中的有效性和安全性方面的改善。此外，新的指南中还增加了处理免疫治疗相关毒性的脚注，以指导临床医生在使用免疫疗法时注意相关毒性的管理。",
  "query": "<question>: 请问针对复发或转移性疾病的治疗方案中，伊立替康在新版指南中有何变化？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: <question>: 请问针对复发或转移性疾病的治疗方案中，伊立替康在新版指南中有何变化？\n\n<reference text>: # NCCN宫颈癌指南2024.V1版较2023.V1版更新内容（续） CERV-F 1/3 宫颈癌的全身治疗 鳞状细胞癌、腺癌或腺鳞癌 ![](images/5f3249131da5b7102251609d0c3f7f2fd153a2a89bf8517ac68126c2586aaade.jpg) # NCCN宫颈癌指南2024.V1版较2023.V1版更新内容（续） CERV-F 1/3 宫颈癌的全身治疗——宫颈小细胞神经内分泌癌 # CERV-F 2 of 3 Small Cell NECC ↓ Recurrent or Metastatic Disease Second-line orSubsequent Therapy; OtherRecommended Regimens:lrinotecanchanged fromcategory 2Btocategory A Footnote f added: NCCN Guidelines for the Management of Immunotherapy-Related Toxicities.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "在新版的NCCN宫颈癌指南中，针对复发或转移性疾病的治疗方案，伊立替康的应用类别有了显著变化。从之前的2B类提升到A类。这意味着伊立替康作为二线或后续治疗方案中的推荐药物，其临床证据得到了更高程度的认可和支持。这样的变化可能反映了伊立替康在相关治疗中的有效性和安全性方面的改善。此外，新的指南中还增加了处理免疫治疗相关毒性的脚注，以指导临床医生在使用免疫疗法时注意相关毒性的管理。"
}